Literature DB >> 15304587

Does Campylobacter jejuni infection elicit "demyelinating" Guillain-Barre syndrome?

S Kuwabara1, K Ogawara, S Misawa, M Koga, M Mori, A Hiraga, T Kanesaka, T Hattori, N Yuki.   

Abstract

BACKGROUND: Campylobacter jejuni enteritis is the most common antecedent infection in Guillain-Barré syndrome (GBS). C. jejuni-related GBS is usually acute motor axonal neuropathy (AMAN), but previous reports described many cases of the demyelinating subtype of GBS (acute inflammatory demyelinating polyneuropathy [AIDP]) after C. jejuni infection.
OBJECTIVE: To investigate whether C. jejuni infection elicits AIDP.
METHODS: In 159 consecutive patients with GBS, antibodies against C. jejuni were measured using ELISA. Antecedent C. jejuni infection was determined by the strict criteria of positive C. jejuni serology and a history of a diarrheal illness within the previous 3 weeks. Electrodiagnostic studies were performed weekly for the first 4 weeks, and sequential findings were analyzed.
RESULTS: There was evidence of recent C. jejuni infection in 22 (14%) patients. By electrodiagnostic criteria, these patients were classified with AMAN (n = 16; 73%) or AIDP (n = 5; 23%) or as unclassified (n = 1) in the first studies. The five C. jejuni-positive patients with the AIDP pattern showed prolonged motor distal latencies in two or more nerves and had their rapid normalization within 2 weeks, eventually all showing the AMAN pattern. In contrast, patients with cytomegalovirus- or Epstein-Barr virus-related AIDP (n = 13) showed progressive increases in distal latencies in the 8 weeks after onset.
CONCLUSION: Patients with C. jejuni-related Guillain-Barré syndrome can show transient slowing of nerve conduction, mimicking demyelination, but C. jejuni infection does not appear to elicit acute inflammatory demyelinating polyneuropathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15304587     DOI: 10.1212/01.wnl.0000133205.05169.04

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  Guillain-Barre syndrome associated with Norovirus infection.

Authors:  Khalid Gailani Eltayeb; Paul Crowley
Journal:  BMJ Case Rep       Date:  2012-06-25

2.  Anti-ganglioside antibodies alter presynaptic release and calcium influx.

Authors:  Brigitte Buchwald; Gang Zhang; Angela K Vogt-Eisele; Weiyi Zhang; Raheleh Ahangari; John W Griffin; Hanns Hatt; Klaus V Toyka; Kazim A Sheikh
Journal:  Neurobiol Dis       Date:  2007-07-14       Impact factor: 5.996

3.  Serial electrophysiological findings in Guillain-Barré syndrome not fulfilling AIDP or AMAN criteria.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Kiichi Unoda; Kazushi Yamane; Yoshimitsu Doi; Shimon Ishida; Fumiharu Kimura; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2016-06-08       Impact factor: 4.849

Review 4.  Guillain-barré syndrome.

Authors:  Satoshi Kuwabara
Journal:  Curr Neurol Neurosci Rep       Date:  2007-01       Impact factor: 5.081

5.  Prospective study on anti-ganglioside antibodies in childhood Guillain-Barré syndrome.

Authors:  J Schessl; M Koga; K Funakoshi; J Kirschner; W Muellges; A Weishaupt; R Gold; R Korinthenberg
Journal:  Arch Dis Child       Date:  2006-08-18       Impact factor: 3.791

6.  Tissue binding patterns and in vitro effects of Campylobacter jejuni DNA-binding protein from starved cells.

Authors:  Hua Piao; Motozumi Minohara; Nobutoshi Kawamura; Wei Li; Takuya Matsushita; Ryo Yamasaki; Yoshimitsu Mizunoe; Jun-Ichi Kira
Journal:  Neurochem Res       Date:  2010-09-19       Impact factor: 3.996

7.  Miller Fisher syndrome linked to Norovirus infection.

Authors:  Taro Shimizu; Yasuharu Tokuda
Journal:  BMJ Case Rep       Date:  2012-12-14

8.  An electrophysiological classification associated with Guillain-Barré syndrome outcomes.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Kiichi Unoda; Kazushi Yamane; Yoshimitsu Doi; Shimon Ishida; Fumiharu Kimura; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2014-08-01       Impact factor: 4.849

Review 9.  Severe Guillain-Barré syndrome in a patient receiving anti-TNF therapy. Consequence or coincidence. A case-based review.

Authors:  Bonifacio Alvarez-Lario; Rosa Prieto-Tejedo; María Colazo-Burlato; Jesús Macarrón-Vicente
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

Review 10.  Guillain-Barré syndrome and anti-ganglioside antibodies: a clinician-scientist's journey.

Authors:  Nobuhiro Yuki
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2012       Impact factor: 3.493

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.